Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors. Elevated levels of serotonin contribute to the gastrointestinal and possibly other symptoms experienced by these patients.

In addition to LX1032, Lexicon has three other drug candidates progressing through various stages of clinical development, including LX1031 for irritable bowel syndrome, LX2931 for rheumatoid arthritis, and LX4211 for diabetes. For more information about Lexicon's clinical development programs, please visit www.lexpharma.com.

"This is an important study, designed to evaluate LX1032's effect on the gastrointestinal symptoms experienced by patients with carcinoid syndrome who have become refractory to current treatment options," said Philip M. Brown, M.D., J.D., senior vice president of clinical development at Lexicon. "We are encouraged by the clinical results obtained to date in which LX1032 demonstrated potent reductions in serotonin production in healthy volunteers."

The Phase 2 clinical trial is designed as a four-week, randomi
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 As pet owners drew up their lists of New ... "Take better care of my furry companion." Nowadays there are pet ... carrying cases to take the little canine or feline darlings along ... to buy some pricey toys at the pet store. But anyone ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... International, Inc. (OTCQX: DATA), a technology and services company ... industry, today announced the award of a Phase III ... A CRO specializing in dermatology, Symbio will be utilizing ... EDC. In an effort to meet the timelines ...
... Reportlinker.com announces that a new market research ... World Bioplastics Industry , ... to increase more than fourfold by 2013 ... plastic resins that are biodegradable or derived from ...
... The positive mix lift expected as farmers choose to ... MON ) to reconfirm its commitment to double its ... Hugh Grant will tell investors today. Speaking at the ... launches for its Genuity(TM) SmartStax(TM) corn and Genuity(TM) Roundup ...
Cached Biology Technology:DATATRAK Signs New Client for Rescue Study 2DATATRAK Signs New Client for Rescue Study 3DATATRAK Signs New Client for Rescue Study 4Reportlinker Adds World Bioplastics Industry 2Reportlinker Adds World Bioplastics Industry 3Reportlinker Adds World Bioplastics Industry 4Reportlinker Adds World Bioplastics Industry 5Reportlinker Adds World Bioplastics Industry 6Reportlinker Adds World Bioplastics Industry 7Reportlinker Adds World Bioplastics Industry 8Reportlinker Adds World Bioplastics Industry 9Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 2Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 3Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 4Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 5Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 6Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 7Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products 8
(Date:4/22/2014)... 2014) Biotechnology scientists must be aware of the ... licensing guidelines, according to a new paper from Rice ... the current issue of the journal Regenerative Medicine ... U.S. Supreme Court ruling in the case Association for ... genes are unpatentable. The court case and rulings garnered ...
(Date:4/22/2014)... of Massachusetts Amherst and the Instituto Nacional de Pesquisas ... have discovered a new genus and species of electric ... the Amazonia State of Brazil. , Professor Cristina Cox ... Antnio Alves-Gomes of INPA, describe the new bluntnose knifefish ... of the Natural Sciences of Philadelphia . , ...
(Date:4/22/2014)... of Kentucky has discovered new methods to build heat ... research, led by Peixuan Guo, professor and William ... of Pharmacy and Markey Cancer Center, is reported in ... Material To Build Robust Structures with Defined Shape and ... Jasinski. , The article, which will appear in a ...
Breaking Biology News(10 mins):New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3New electric fish genus and species discovered in Brazil's Rio Negro 2RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2
... SANTA CRUZ, CA--Observations at submarine springs found along the ... preview of the possible fate of coral reef ecosystems ... pH (a measure of acidity) in the water around ... result from the widespread acidification of surface waters that ...
... Electronic infrastructures open new horizons for collaboration and acceleration ... such as scratchpads.eu , yield opportunities, ... newly collected data coming from different sources and working ... journal ZooKeys presenting the results ...
... FAIRFAX, Va.Researchers have published the largest single patient ... following patients with retrievable inferior vena cava (IVC) ... to the lungs. This study, which is important ... supports existing guidelines developed by the Society of ...
Cached Biology News:Submarine springs offer preview of ocean acidification effects on coral reefs 2Submarine springs offer preview of ocean acidification effects on coral reefs 3Electronic infrastructures accelerate biodiversity discoveries 2IVC filters: Society of Interventional Radiology leads in patient care, safety, research 2IVC filters: Society of Interventional Radiology leads in patient care, safety, research 3
Request Info...
...
Candida (IgG) -Ab EIA Sample Size: 5 l...
Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
Biology Products: